Elimination | Peer Reviewed Journals
Medical & Surgical Urology

Medical & Surgical Urology
Open Access

ISSN: 2168-9857


"The clinical advantage of PEG-IFNa-2B results from the fact that it is very slowly cleared after administration, resulting in a longer terminal elimination half-life (t 1/2 ) and a higher systemic exposure (both AUC and C max ) in both preclinical and clinical studies conferring an increased efficacy compared to IFNa-2B. The pegylation of IFNa- 2B also renders the molecule less immunogenic; Pegasys ® (pegylated Interferon a) is less immunogenic than Roferon ® (native Interferon a). The toxicokinetic profile of PEG-IFNa-2B obtained in a GLP preclinical toxicology study involving the repeated administration of the biopharmaceutical for 13 weeks by the subcutaneous route in Macaca fascicularis. 

High Impact List of Articles
Conference Proceedings

Relevant Topics in Medical Sciences